After hours: January 17 at 7:59:54 PM EST Loading Chart for SAVA ...

After hours: January 17 at 7:59:54 PM EST ...

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the end. The Austin, Texas-based biotech revealed that simufilam failed its ...

Cassava is advancing simufilam through a pivotal phase 3 trial, despite lingering controversy from a SEC investigation. As the company prepares to release trial results, Ben Hargreaves finds that ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 ...

Microsoft is grateful for the trust that people place in our products, services, and experiences. These Trademark and Brand Guidelines (“Trademark Guidelines”) detail how you can help us protect ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Got some milk, flour, and eggs? Then you’re already on your way to making some delicious, crunchy Nigerian buns! These tasty treats are a popular snack - BellaNaija.com. January 17, 2025 ...